Winklevoss Capital led a $58.88M PIPE in Leap Therapeutics (Nasdaq:LPTX), a biotech company, to initiate a digital asset treasury strategy. Winklevoss Capital gets right to nominate two board members, including the chairperson.
OCT 6, 2025
Clinical-stage biopharmaceutical company developing novel therapies for cancer, including antibody-based treatments targeting tumor biology and immune pathways
Clinical-stage biopharmaceutical company developing novel therapies for cancer, including antibody-based treatments targeting tumor biology and immune pathways. The supplied search results contain only cookie-consent content, so company-specific details are based on the company identity and domain and are not substantiated by the retrieved page text.